SLC66A2

Across TCGA pan-cancer cohorts, SLC66A2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of SLC66A2’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where SLC66A2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types SLC66A2 is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.

LSCC, LUAD, and CCRCC are the cancer types where SLC66A2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC66A2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Female	All	−0.486	<.001	7	view →
LUAD	Male	All	−0.285	<.001	6	view →
CCRCC	Male	All	−0.393	<.001	5	view →
PDAC	Male	All	−0.705	.007	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

SLC66A2–LSCC

Open the LSCC breakdown →